ONCY Stock Analysis: Buy, Sell, or Hold?
ONCY - Oncolytics Biotech, Inc. Common Shares
$0.85
-0.05 (-5.50%)
▼
5d:
-26.01%
30d:
+5.7%
90d:
-23.34%
WAIT
LOW Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 13, 2026
13d
Get Alerted When ONCY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ONCY is down 26.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ONCY is down 26.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ONCY is currently trading at $0.85, which is considered oversold relative to its 30-day fair value range of $0.88 to $1.07.
Technical Outlook: Technically, ONCY is showing sideways momentum. The price is currently testing key support at $0.84. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.15 (+472.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ONCY is showing sideways momentum. The price is currently testing key support at $0.84. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.15 (+472.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.88 -
$1.07
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.5%)
- BULLISH: Trading 472.0% below Wall St target ($5.15)
- WARNING: Recommendation downgraded due to -26.0% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.88 -
$1.07
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.84
Resistance Level
$1.19
Current Trend
Sideways
Technical data as of
Apr 29, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.46
Wall Street Target
$5.15
(+472.0%)
Share & Embed Analysis
Last updated: April 29, 2026 12:49 PM ET
Data refreshes hourly during market hours. Next update: 1:49 PM
Data refreshes hourly during market hours. Next update: 1:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ONCY showing a specific setup today?
Insider Activity (6 Months)
14
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Jared Kelly
BUY
5050 shares
2026-03-12
James T Parsons
BUY
10000 shares
2026-03-11
Allison Hagerman
BUY
10000 shares
2026-02-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$224 | 64 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$27 | 57 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$131 | 55 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 53 HOLD |
